 | | Vol. 11.39 – 16 October, 2020 |
| |
|
|
| Single-cell mRNA-sequencing analysis of the highly metabolically (hm) active cells from metastatic prostate cancer patients revealed that approximately 10% were canonical EpCAM+ hm-circulating tumor cells (CTCs), 3% were EpCAM− hm-CTCs with upregulation of prostate-related genes, and 87% were hm-circulating stromal cells with profiles characteristic for cancer-associated fibroblasts, mesenchymal stem cells, and endothelial cells.
[Science Advances] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists demonstrated for the first time, that lineage switching to neuroendocrine states was accompanied by key miRNA alterations including downregulation of miR-106a~363 cluster and upregulation of miR-301a and miR-375. They identified novel miRNA neuroendocrine differentiation drivers that could be exploited for neuroendocrine prostate cancer therapeutic targeting.
[Oncogene] |
|
|
|
| The authors report a physiologically relevant assay enabling quantitative analysis of metastatic capacity of tumor cells following implantation into the CAM. Engraftment of as few as 103 non-small cell lung cancer and prostate cancer cell lines was sufficient for both primary tumor and metastasis formation.
[Scientific Reports] |
|
|
|
| Researchers undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate), MBT-2 (bladder) and Renca (kidney) were used.
[Scientific Reports] |
|
|
|
| The authors suggested that ROS-mediated genotoxic stress is involved in NaAsO2-induced cell cycle arrest, stemness enhancement and chemoresistance of prostate cancer cells in a p53-independent manner.
[Ecotoxicology and Environmental Safety] |
|
|
|
| Investigators studied metastatic deposits of prostate cancers with isoform-specific ΔNp63 and TAp63 antibodies. They identified p63-positive cells in only 3 of 42 metastatic prostate tumors, including 2/38 “usual-type” adenocarcinomas. ΔNp63 and TAp63 isoforms were present in the nuclei of less than 1% of tumor cells in these metastases.
[Virchows Archiv] |
|
|
|
| Scientists observed that DLX6‐AS1 was significantly upregulated in prostate cancer (PCa) tissues and cells. Knockdown of DLX6‐AS1 inhibited PCa progression by suppressing cell proliferation and accelerating cell apoptosis.
[Environmental Toxicology] |
|
|
|
|
| Th authors summarize current knowledge of the main gene fusions in genitourinary malignancies, discuss their growing importance in the understanding of the biology of tumours, and highlight their potential use as targets for precision medicine approaches.
[Nature Reviews Urology] |
|
|
|
|
| Clinical Laserthermia Systems and Otto-von-Guericke-University Magdeburg Medical faculty are entering into an agreement regarding an Investigator Initiated Trial targeting MRI-Ultrasound fusion guided focal laser ablation treatment of prostate cancer.
[Clinical Laserthermia Systems AB (publ)] |
|
|
|
|
| January 25 – January 28, 2021
Virtual |
|
|
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | University of Southern Denmark – Odense M, Denmark |
|
|
|
| | University of Texas Southwestern Medical Center – Dallas, Texas, United States |
|
|
|
| | Princess Margaret Cancer Center – Toronto, Ontario, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
